Low frequency of altered biodistribution detected by Indium-111 imaging prior to yttrium-90 ibritumomab tiuxetan radioimmunotherapy: Imaging registry results

Peter S. Conti,Christine A. White,Peter C. Pieslor,G. Menéndez,V. D. Harrough,Dan Matso,Jacqueline Aussie,T Ryskamp,Paul A. Foster

Low frequency of altered biodistribution detected by Indium-111 imaging prior to yttrium-90 ibritumomab tiuxetan radioimmunotherapy: Imaging registry results

2005

Peter S. Conti
Christine A. White
Peter C. Pieslor
G. Menéndez
V. D. Harrough
Dan Matso
Jacqueline Aussie
T Ryskamp
Paul A. Foster

6589 Background: Ibritumomab tiuxetan (Zevalin) therapy consists of a rituximab pre-dose followed by indium-111 ibritumomab tiuxetan (111In IT) for imaging on day 1 and yttrium 90 (90Y) IT for ther...

Keywords:

Nuclear medicine
Indium
Yttrium-90 Ibritumomab Tiuxetan
Pathology
Radioimmunotherapy
Biodistribution
Medicine
Yttrium
Ibritumomab tiuxetan
Rituximab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations